Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome - Clinical study about the safety of Orexin receptor antagonist Suvorexant for severe sleep apnea syndrome

There is no significant difference in AHI (median: 48.3 times/hour on the first night, 50.2 times/hour on the second night p=0.58). Among the secondary endpoints, significant differences were found in sleep efficiency (median: 82.8% on first night, 87.8% on second night, p=0.004), REM sleep rate (median: 15.0% on first night, 21.2% on second night, p<0.001). There was no significant difference in the AHI of patients with severe sleep apnea before and after taking Suvorexant.